Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident cases, approximately 85% are the non-small cell lung cancer (NSCLC) subtype. NSCLC patients are usually diagnosed in the later stages of the disease, with poor prognosis. Historically, treatment options for advanced-stage NSCLC patients have been dominated by chemotherapy. However, the launch of targeted therapies such as Iressa (gefitinib) in 2003, Tarceva (erlotinib) in 2004, and Xalkori (crizotinib) in 2011, has shifted the treatment landscape towards personalized medicine.
In 2015, the NSCLC market in China was an estimated $445M. This growth is fueled by the use of immunotherapies across histologies and lines of therapy in NSCLC, as well as increased access to drugs. Currently, PD-1 inhibitors have not yet launched in China, and thus, there is significant untapped potential for this class of drugs, both in the first- and second-line settings in the Chinese market.
*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.
Overview of NSCLC including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on the key drugs in China including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for the top drugs in China from 2015-2025.
Analysis of the impact of key events as well the drivers and restraints affecting China NSCLC market.
Reasons To Buy
Understand and capitalize by identifying products that are most likely to ensure a robust return
Stay ahead of the competition by understanding the changing competitive landscape for NSCLC.
Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
Make more informed business decisions from insightful and in-depth analysis of drug performance
Obtain sales forecast for drugs from 2015-2025 in China.